The immediate implication of this study for policy-makers is that in the Hong Kong context PHI is likely to be a cost-saving addition to the diagnostic set-up for prostate cancer in men with PSA levels of 4-10ng/ml and negative DRE. This evidence concerns the gene KLK3 and prostate carcinoma.